Jenna Fletcher is a freelance writer and content creator. She writes extensively about health and wellness. As a mother of one stillborn twin, she has a personal interest in writing about overcoming grief and postpartum depression and anxiety, and reducing the stigma surrounding child loss and mental healthcare. She holds a bachelorâs degree from Muhlenberg College.\n"},"avatar":{"title":"","width":500,"height":500,"src":"https://post.medicalnewstoday.com/wp-content/uploads/sites/3/2020/06/500x500_Jenna_Fletcher.png"}}],"medicalReviewers":[{"id":5097,"name":{"display":"Megan Soliman, MD","first":"Megan","last":"Soliman, MD"},"userLogin":"msoliman","links":{"website":"","facebook":"","linkedin":"","twitter":"","instagram":"","tiktok":""},"link":"/reviewers/megan-soliman-md","type":{"value":"medical_reviewer","label":"Medical Advisor"},"nid":"","specialties":[],"guestTitle":"","bio":{"text":"
Infusion reactions, also known as acute infusion reactions or infusion-related reactions, are common adverse effects that can occur when a person receives medication intravenously.
Infusion reactions occur during or following an intravenous (IV) infusion, or IV therapy, which is medication administered by a doctor into a vein. Reactions can range from mild to potentially life threatening.
This article explores what infusion reactions are, symptoms, diagnosis, treatment, prevention, and management.
According to the American Cancer Society, infusion reactions may occur when the body has a strong immune response to certain treatments given via IV, such as cancer treatments. Infusion reactions may occur immediately or some time after the infusion.
The severity of a reaction depends on the dose and other factors, such as the specific medication or health condition.
Research from 2018 classifies adverse reactions to treatment into several categories with letter designations:
A: augmented pharmacological effects
B: bizarre
C: chronic effects
D: delayed effects
E: end of treatment effects
F: failure of therapy
Classifications of infusion reactions
The research classifies infusion reactions under type B because they are:
unpredictable
not dependent on dose
often not related to the effects of the medication
self-clearing at the end of treatment
However, some experts suggest that healthcare professionals may be able to predict certain reactions, such as ones associated with immunotherapy medications, based on the exact agent given.
Allergic and nonallergic reactions
The 2018 research further divides reactions into allergic and nonallergic subtypes. Allergic infusion reactions occur when the immune system overreacts. They can include severe reactions such as anaphylactic shock.
A 2020 study describes immune responses as innate, adaptive, or both. Innate refers to a general, rapid response from the immune system. An adaptive immune response involves a more targeted reaction from the immune system when it recognizes a trigger.
idiosyncratic reactions, which are unpredictable, unrelated to the medication, and uncommon
intolerances, such as a reaction to the medication
According to another 2018 study, most cases of infusion reactions are nonallergic types.
A person may develop a mild reaction or a potentially life threatening reaction that requires emergency medical treatment. Regardless of reaction type, an infusion reaction typically occurs within 30â120 minutes after infusion but may take anywhere from 24 hours to 1 week for symptoms to start.
Cancer treatments and reactions
The National Cancer Instituteâs common terminology criteria for adverse events describes adverse events, such as infusion reactions, based on grade (symptom severity). Grades range from 1â5. Grade 1 indicates mild symptoms, while grade 5 is for death.
According to a 2019 systematic literature review, about 5% of people receiving monoclonal antibody drugs for colorectal cancer experienced infusion reactions. They also noted that the grade of severity and type of therapy both influenced the occurrence of infusion reactions.
Reactions to chemotherapy medications may also occur and be severe. However, a 2017 study found that infusion reactions due to antineoplastic agents (a type of chemotherapy medication) were rare.
Research from 2022 suggests that fewer than 5% of people receiving immunotherapy have an infusion reaction.
Infusion reactions not related to cancer treatment
Infusion reactions may also occur with other IV infusions not related to cancer treatment.
A 2022 study examined the adverse events associated with iron infusions for the treatment of iron deficiencies. The study included over 12,000 people with iron deficiencies and found an incidence rate of about 3.9% of infusion reactions.
Of those who experienced a reaction, only two people required an epinephrine (EpiPen) injection to treat a severe reaction. Otherwise, the majority of those who developed a reaction experienced only minor symptoms.
According to the American Cancer Society, symptoms from an infusion reaction may start while a person receives treatment or potentially several days or weeks following the infusion.
General effects
Symptoms associated with infusion reactions can include:
In general, the faster the symptoms appear, the more likely a person is to develop a severe reaction.
Immunotherapy effects
People who receive immunotherapy are unlikely to have an infusion reaction. However, if one does occur, cytokine release is one of thepossible causes of the reaction. This can mimic symptoms of anaphylaxis but requires different treatment.
Diagnosis requires healthcare professionals to recognize the signs and symptoms associated with infusion reactions.
Once home, a person should also monitor for possible symptoms associated with infusion reactions. If symptoms occur, a person should let a healthcare professional know as soon as possible or seek emergency services if symptoms become severe.
If a reaction occurs, a doctor or other healthcare professional will assess the symptoms to determine whether a person requires lifesaving treatments.
Anaphylaxis is highly likely when a personâs symptoms fulfill one of the following three sets of criteria:
acute onset of an illness (within minutes to hours), which typically involves the skin or mucous membranes, including:
reduced blood pressure after exposure to a known allergen (minutes to several hours)
Blood or urine tests to detect biomarkers may also help diagnose anaphylaxis.
Doctors will test for urinary histamine metabolites, which they may find up to 24 hours after the onset of anaphylaxis. They will measure tryptase levels in blood samples 15 minutes to 3 hours after symptom onset.
However, anaphylaxis can also occur without elevated levels of certain chemicals. Generally, the recommendation is to begin treatment before these results come back.
For the treatment of nonallergic reactions, healthcare professionals will typically stop the infusion, treat a personâs symptoms, and resume the infusion at half the previous rate once the symptoms go away.
Healthcare professionals will discuss medical history, including past reactions to infusions, with the person. Though experts cannot predict whether a reaction will happen again, it can make them more aware of the possibility.
They may ask if a person took certain medications before the infusion, sometimes called premedications. Taking these may help with preventing infusion reactions. Examples include corticosteroids and antihistamines.
If symptoms occur during an infusion, healthcare professionals should recognize them. They will likely stop the infusion if they suspect a reaction is occurring.
Once the healthcare professional has addressed a personâs symptoms, they can help determine whether treatment should stop or whether they can continue with the infusion.
Infusion reactions can range from mild to life threatening. They may be allergic or nonallergic reactions. Moderate to severe symptoms typically require treatment such as symptom management and, in some cases, lifesaving therapy.
Healthcare professionals cannot predict whether a person will develop an infusion reaction. They should discuss medical history with the person and watch for signs of a severe reaction developing. People should contact a doctor if any unusual symptoms occur following an infusion.
Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
Bylsma LC, et al. (2019). The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta‐analysis of patient and study characteristics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745824/
Rombouts MD, et al. (2020). Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. https://ar.iiarjournals.org/content/40/3/1201